191 related articles for article (PubMed ID: 30630775)
21. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
22. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
23. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
24. Status of vaccine research and development of vaccines for tuberculosis.
Evans TG; Schrager L; Thole J
Vaccine; 2016 Jun; 34(26):2911-2914. PubMed ID: 26973073
[TBL] [Abstract][Full Text] [Related]
25. [Technical guidelines for seasonal influenza vaccination in China (2023-2024)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Oct; 44(10):1507-1530. PubMed ID: 37875437
[TBL] [Abstract][Full Text] [Related]
26. Epitope promiscuity and population coverage of Mycobacterium tuberculosis protein antigens in current subunit vaccines under development.
Ong E; He Y; Yang Z
Infect Genet Evol; 2020 Jun; 80():104186. PubMed ID: 31923726
[TBL] [Abstract][Full Text] [Related]
27. Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study.
Shrestha S; Chihota V; White RG; Grant AD; Churchyard GJ; Dowdy DW
Am J Epidemiol; 2017 Dec; 186(12):1362-1369. PubMed ID: 29253139
[TBL] [Abstract][Full Text] [Related]
28. Vaccines for preventing influenza in healthy adults.
Demicheli V; Jefferson T; Ferroni E; Rivetti A; Di Pietrantonj C
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD001269. PubMed ID: 29388196
[TBL] [Abstract][Full Text] [Related]
29. New tuberculosis vaccines: advances in clinical development and modelling.
Weerasuriya CK; Clark RA; White RG; Harris RC
J Intern Med; 2020 Dec; 288(6):661-681. PubMed ID: 33128834
[TBL] [Abstract][Full Text] [Related]
30. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Oct; 43(10):1515-1544. PubMed ID: 36456484
[TBL] [Abstract][Full Text] [Related]
31. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
[TBL] [Abstract][Full Text] [Related]
33. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
[TBL] [Abstract][Full Text] [Related]
34. The potential impact of vaccination on tuberculosis burden in India: A modelling analysis.
Arinaminpathy N; Rade K; Kumar R; Joshi RP; Rao R
Indian J Med Res; 2023; 157(2&3):119-126. PubMed ID: 37202930
[TBL] [Abstract][Full Text] [Related]
35. Preventive vaccines for tuberculosis.
Evans TG; Brennan MJ; Barker L; Thole J
Vaccine; 2013 Apr; 31 Suppl 2():B223-6. PubMed ID: 23598486
[TBL] [Abstract][Full Text] [Related]
36. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
37. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
38. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.
Knight GM; Griffiths UK; Sumner T; Laurence YV; Gheorghe A; Vassall A; Glaziou P; White RG
Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15520-5. PubMed ID: 25288770
[TBL] [Abstract][Full Text] [Related]
39. The roles of latency-associated antigens in tuberculosis vaccines.
Yousefi Avarvand A; Khademi F; Tafaghodi M; Ahmadipour Z; Moradi B; Meshkat Z
Indian J Tuberc; 2019 Oct; 66(4):487-491. PubMed ID: 31813436
[TBL] [Abstract][Full Text] [Related]
40. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study.
GBD Tuberculosis Collaborators
Lancet Infect Dis; 2018 Dec; 18(12):1329-1349. PubMed ID: 30507459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
